Roche Archives - Page 4 of 6 - Medical Design Sourcing

Biosimilars adoption growing, but the market remains nascent

Photo by Tara Winstead from Pexels

While biosimilar adoption remains at an early stage in the U.S., biosimilar adoption is ticking up. Biosimilar penetration for Roche’s Avastin (bevacizumab) is especially high at 69%. In addition, biosimilars for Genentech’s Herceptin and Amgen’s Neupogen have also achieved a market penetration of 57% and 62%, respectively, according to IQVIA data based on late June sales data.

One of the chief factors limiting the size of the biosimilars market, however, is the limited number of biosimilars on the market. While the Affordable Care Act included biosimilar provisions, only 33 biosimilars have won FDA approval since 2015. The agency approved ten of those in 2019.

The Biosimilars Council estimates that biosimilars could save the U.S. as much as $130 billion by 2025.

For now, however, overall adoption remains at a nascent stage. “Various factors have likely influe…

Europe approves Roche’s Enspryng subcutaneous NMOSD treatment

Roche (SWX: RO, ROG) announced today that the European Commission approved its Enspryng subcutaneous NMOSD treatment.

Basel, Switzerland-based Roche developed Enspryng (satralizumab) to treat adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD).

Get the full story at our sister site, Drug Delivery Business News.

Roche wins EUA for intravenous tocilizumab in treating COVID-19

Roche announced today that it received FDA emergency use authorization (EUA) for intravenous Actemra/RoActemra in treating COVID-19.

Basel, Switzerland-based Roche’s Actemra/RoActemra (tocilizumab) drug received authorization to treat COVID-19 in hospitalized adults and pediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).

Get the full story at our sister site, Drug Discovery & Development.

Roche wins EUA for intravenous tocilizumab in treating COVID-19

Roche announced today that it received FDA emergency use authorization (EUA) for intravenous Actemra/RoActemra in treating COVID-19.

Basel, Switzerland-based Roche’s Actemra/RoActemra (tocilizumab) drug received authorization to treat COVID-19 in hospitalized adults and pediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).

Actemra/RoActemra is the first humanized interleukin-6 (IL-6) receptor antagonist approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have used one or more disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX), that did not provide enough relief, Roche said in a news release.

According to the release, Roche garnered authorization based on results from four randomized, controlled studies eva…

FDA accepts biologics license application for Genentech’s drug-eluting eye implant

Genentech’s PDS implant. [Image from Genentech]Genentech announced that the FDA accepted its Biologics License Application (BLA) for its Port Delivery System (PDS) with ranibizumab.

PDS, a permanent, refillable eye implant standing at the approximate size of a grain of rice offers continuous delivery of a customized formulation of ranibizumab over a period of months with the intention of reducing the treatment burden associated with frequent eye injections.

Get the full story at our sister site, Drug Delivery Business News.

COVID-19 treatments will continue to lift pharma sector, according to Moody’s

Photo by Anna Shvets from Pexels

The pandemic has eased throughout much of the world. But demand for COVID-19 vaccines and treatments continues to be brisk, according to ratings agency Moody’s. In general, the pandemic will contribute to the pharmaceutical industry’s projected EBITDA growth rate of 4% to 6% over the coming 12 to 18 months, the firm concluded.

While a significant number of vaccines and antivirals are already in use, more will likely win regulatory authorization in the coming months. But the volume of future COVID-19 therapy sales will hinge upon “how the pandemic evolves,” the Moody’s report acknowledged.

Other factors driving growth include growing healthcare use as countries such as the U.S. continue to lift COVID-19 restrictions.

Oncology, one of the most rapidly growing pharma areas, is likely to continue its growth trajectory. Moody’s expects immuno-onco…

10 of the best pharma companies to work for

The pharmaceutical industry is on the upswing and is poised to have a compound annual growth rate of 13.7% from 2020 to 2027, according to projections from Grand View Research.

The industry’s resurgence is a good opportunity for employees in the sector, who frequently enjoy comfortable salaries.

To get a sense of which pharmaceutical companies in the sector were the best employers, we sifted through data on company reviews sites Glassdoor and Comparably, and other sources.

Here are the 10 companies that came in on top:

Get the full story from our sister site, Drug Discovery & Development.

10 of the best pharma companies to work for

The pharmaceutical industry is on the upswing and is poised to have a compound annual growth rate of 13.7% from 2020 to 2027, according to projections from Grand View Research.

The industry’s resurgence is a good opportunity for employees in the sector, who frequently enjoy comfortable salaries.

To get a sense of which pharmaceutical companies in the sector were the best employers, we sifted through data on company reviews sites Glassdoor and Comparably, and other sources.

Here are the 10 companies that came in on top.

Get the full story from our sister site, Drug Discovery & Development.

And browse data on all the Pharma 50 companies here.

10 of the best pharma companies to work for

The pharmaceutical industry is on the upswing and is poised to have a compound annual growth rate of 13.7% from 2020 to 2027, according to projections from Grand View Research.

The industry’s resurgence is a good opportunity for employees in the sector, who frequently enjoy comfortable salaries.

To get a sense of which pharmaceutical companies in the sector were the best employers, we sifted through data on company reviews sites Glassdoor and Comparably, and other sources.

Below are the 10 companies that came in on top. (And browse data on all the Pharma 50 companies here.)

1. Sage Therapeutics

Glassdoor rating: 4.4/5 83% would recommend to a friend

Pros: Workers at Sage Therapeutics applauded the company’s work-life balance and culture. Just under three-quarters (74%) had a positive business outlook for the firm. One recent reviewer found meaning in “doing the toughest job in the world by developing CNS drugs.” The company’s brain health p…

Insulet sues Roche over diabetes tech patent

Insulet (NSDQ:PODD) is suing Roche Diabetes Care in the U.K., claiming that Roche prematurely began selling tubeless insulin pumps covered by an Insulet patent three years before that patent expires.

The trial for the lawsuit, filed in August 2020, began this week in the U.K. High Court.

Insulet claims that Roche has been infringing the patent on its Omnipod insulin pump by marketing Roche’s Accu-Chek Solo pump since mid-2018. Accu-Chek received the CE mark in July of that year. Insulet also claims that Roche is indirectly infringing its patent by marketing “consumable” products needed to operate its Accu-Chek pumps in the U.K.

Get the full story from our sister site, Drug Delivery Business.

Pharma’s top 20 R&D spenders in 2020

[Lab image by Michal Jarmoluk from Pixabay]The past year has been an unprecedented time for the pharmaceutical industry.

On the one hand, the pandemic resulted in substantial delays to clinical trials while also forcing sponsors to rethink clinical trial design to protect participants. But on the other hand, the pandemic underscored the importance of the pharma industry in society.

While the pandemic certainly was a driver for substantial R&D spending in the industry in 2020, a significant expense for many companies last year was licensing fees and other acquisition costs. That trend is not just apparent for Incyte, which tops this list, but also for several other companies in this ranking of 20 firms, which are ranked below based on the percent of revenue they invest in R&D. (To find out the top 50 pharma companies, check out our recently published ranking here.)

Get the full picture from our sister site, Drug Discovery & Development.

Pharma’s top 20 R&D spenders in 2020

[Lab image by Michal Jarmoluk from Pixabay]

The past year has been an unprecedented time for the pharmaceutical industry.

On the one hand, the pandemic resulted in substantial delays to clinical trials while also forcing sponsors to rethink clinical trial design to protect participants. But on the other hand, the pandemic underscored the importance of the pharma industry in society.

While the pandemic certainly was a driver for substantial R&D spending in the industry in 2020, a significant expense for many companies last year was licensing fees and other acquisition costs. That trend is not just apparent for Incyte, which tops this list, but also for several other companies in this ranking of 20 firms, which are ranked below based on the percent of revenue they invest in R&D. (To find out the top 50 pharma companies, check out our recently published ranking here.)